Surat, November 15, 2024: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and half year ended September 30, 2024.

Consolidated Financial Highlights for half year ended September 30, 2024:

• Total revenue for H1FY25 was at ₹5,562 million as compared to ₹7,944 million in H1FY24.
• EBITDA (incl. other income) was at ₹1,416 million in H1FY25 as compared to ₹2,247 million in H1FY24, this would translate into 25% EBITDA margin in H1FY25.
• Profit After Tax was at ₹428 million in H1FY25 as compared to ₹1,009 million in H1FY24.

Consolidated Financial Highlights for Quarter ended September 30, 2024:

• Total revenue for Q2FY25 was at ₹2,959 million as compared to ₹3,956 million in Q2FY24.
• EBITDA (incl. other income) was at ₹824 million in Q2FY25 as compared to ₹1,109 million in Q2FY24, this would translate into 28% EBITDA margin in this quarter.
• Profit After Tax was at ₹306 million in Q2FY25 as compared to ₹487 million in Q2FY24.

Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented, “In Q2FY25, we were nearing the end of a demand slump in the Agro segment, and we are now seeing a good recovery. The Pharma and Polymer segments, meanwhile, have been showing robust growth, fuelled by the launch of over 17 new molecules in FY24 and 3 additional molecules in H1FY25. As these products gain traction, we expect their contribution to grow. Additionally, the planned launch of more than 3 new molecules in the coming months should further accelerate growth in these areas.

Our consolidated operating revenue for the quarter was ₹294 crores, representing a QoQ growth of 14%, with a stable EBITDA margin of 28% in Q2FY25. We anticipate revenue to normalize as volumes increase in the latter half of the year. With the new capacity, scaling of recently launched fluorinated molecules, and signed LOIs and contracts, we are optimistic about strong growth over the medium term.”